Advances in the study of BRAF V600E mutation in the treatment of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2020.03.015

Abstract

Abstract:

Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related deaths worldwide. Constitutive activation of Ras-Raf-Mek-Erk (MAPK) pathway plays an important role in the occurrence and development of CRC. V-raf murine sarcoma viral oncogene homolog (BRAF) is a kinase in the MAPK signaling pathway and plays an important role in the development of colorectal cancer. Clinical observations showed that BRAF V600E was found in approximately 8%~10% of CRC cases and was associated with significantly lower median overall survival. It has predictive value for the prognosis of colorectal cancer. A preliminary study on BRAF V600E mutation provides a new idea for molecular targeted therapy of colorectal cancer.

Key words: Colorectal neoplasms, BRAF mutation, MSI, Targeted therapy

Xiangtao Zhang, Ruiqing Liu, Xianxiang Zhang, Yun Lu. Advances in the study of BRAF V600E mutation in the treatment of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(03): 292-295.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.03.015

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I03/292

References 51

[1]	Das TM, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, 2013 [J]. Nature, 2013, 494(7436): 251-255.
[2]	Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, 2014 [J]. Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 2014, 20(7): 1965.
[3]	Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, 2010 [J]. Nature, 2010, 468(7326): 973.
[4]	Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, 2012 [J]. Nature, 2012, 483(7387): 100.
[5]	Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer, 2012 [J]. Cancer Research, 2012, 72(3): 779.
[6]	Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer, 2009 [J]. Nat Rev Cancer, 2009, 9: 489-499.
[7]	Ewing I, Hurley JJ, Josephides E, et al. The molecular genetics of colorectal cancer, 2014 [J]. Frontline Wastroenterol, 2014, 5(1): 26-30.
[8]	Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis, 2014 [J]. Eur J Cancer Prev, 2014, 23(4): 246-257.
[9]	Lengauer C, Kinzler KW, Vogelstein B, et al. Genetic instability in colorectal cancers, 1997 [J]. Nature, 1997, 386: 623-627.
[10]	Gordon DJ, Resio B, Pellman D, et al. Causes and consequences of aneuploidy in cancer, 2012 [J]. Nat Rev Genet, 2012, 13: 189-203.
[11]	Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, 2007 [J]. Histopathology, 2007, 50: 113-130.
[12]	Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, 2006 [J]. Nat Genet, 2006, 38: 787-793.
[13]	Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors, 1998 [J]. Gut, 1998, 42: 673-679.
[14]	Walther A, Houlston R, Tomlinson I, et al. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis, 2008 [J]. Gut, 2008, 57: 941-950.
[15]	Watanabe T, Kobunai T, Yamamoto Y, et al. Chromosomal instability(CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer, 2012 [J]. J Clin Oncol, 2012, 30(18): 2256-2264.
[16]	Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients, 2006 [J]. Gastroenterology, 2006, 131: 729-737.
[17]	Popat S, Hubner R, Houlston RS, et al. Systematic review of microsatellite instability and colorectal cancer prognosis, 2005 [J]. J Clin Oncol, 2005, 23: 609-618.
[18]	Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy, 2011 [J]. J Natl Cancer Inst, 2011, 103: 863-875.
[19]	Müller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group, 2008 [J]. Int J Colorectal Dis, 2008, 23: 1033-1039.
[20]	Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, 2005 [J]. Cancer Res, 2005, 65: 6063-6069.
[21]	Ogino S, Shima K, Meyerhardt J, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, 2012 [J]. Clin Cancer Res, 2012, 18(3): 890-900.
[22]	Bond CE, Nancarrow DJ, Wockner LF, et al. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability [J]. PLoS ONE, 2014, 9(3): e91739.
[23]	Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas, 2004 [J]. Int J Cancer, 2004, 108: 237-242.
[24]	Sérgia V, Cátia M, Luís C, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis, 2008 [J]. BMC Cancer, 2008, 8: 255.
[25]	Riccio A, Aaltonen LA, Godwin AK, et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability, 1999 [J]. Nature Genetics, 1999, 23(3): 266-268.
[26]	Tricarico R, Cortellino S, Riccio A, et al. Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis, 2015 [J]. Oncotarget, 2015, 6(40): 42892.
[27]	Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer, 1999 [J]. Proc Nati Acad Sci USA, 1999, 96: 8681-8686.
[28]	孙乃恩，孙东旭，朱德煦. 分子遗传学[M]. 南京: 南京大学出版社, 2001.
[29]	O′Brien MJ. Hyperplastic and serrated polyps of the colorectum, 2007 [J]. Gastroenterol Clin North Am, 2007, 36: 947-968,viii.
[30]	Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instabilityand is tightly associated with BRAF mutation in colorectal cancer, 2006 [J]. Nat Genet, 2006, 38: 787-793.
[31]	Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG islandmethylator phenotype in colon cancer, 2005 [J]. Gastroenterology, 2005, 129: 837-845.
[32]	Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer [J]. Nat Genet, 2006, 38(7): 787-793.
[33]	Kambara T, SimmsL A, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum, 2004 [J]. Gut, 2004, 53(8): 1137-1144.
[34]	Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis, 2007 [J]. Journal of Pathology, 2007, 212(2): 124-133.
[35]	Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort, 2012 [J]. European Journal of Cancer, 2012, 48(1): 94-100.
[36]	Santarpia L, Lippman SM, Elnaggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy, 2012 [J]. Expert Opinion on Therapeutic Targets, 2012, 16(1): 103-119.
[37]	Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, 2004 [J]. Cell, 2004, 116: 855-867.
[38]	Xiong J, He M, Hansen K, et al. The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma, 2016 [J]. Gynecol Oncol, 2016, 142: 163-168.
[39]	Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy, 2014 [J]. Pharmacol Ther, 2014, 142: 176-182.
[40]	Fang M, Ou J, Hutchinson L, et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype, 2014 [J]. Molecular Cell, 2014, 55(6): 904-915.
[41]	Martín Martorell P, Huerta M, Compañ Quilis A, et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients, 2017 [J]. Clin Lung Cancer, 2017, 18(6): e395-e402.
[42]	宋敏，孙亚琼，张莉，等. 结直肠癌组织KRAS和BRAF基因突变情况及意义[J]. 山东医药, 2014, (32): 32-34.
[43]	Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumabor cetuximab in metastatic colorectal cancer, 2008 [J]. J Clin Oncol, 2008, 26(35): 5705-5712.
[44]	Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma, 2010 [J]. N Engl J Med, 2010, 363(9): 809-819.
[45]	Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, 2014 [J]. N Engl J Med, 2014, 371(20): 1877-1888.
[46]	Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, 2005 [J]. PLoS Med, 2005, 2(3): e73.
[47]	Kopetz S, Desai J, Chan E, et al. Phase Ⅱ pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer, 2015 [J]. J Clin Oncol, 2015, 33(34): 4032-4038.
[48]	Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer [J]. J Clin Oncol, 2015, 33(34): 4023-4031.
[49]	Kopetz S, McDonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406), 2017 [J]. J Clin Oncol, 2017, 35: 520.
[50]	Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in V600E-mutated colorectal cancer.N, 2015 [J]. Engl J Med, 2015,10.1056/NEJMoa1908075.
[51]	Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency, 2015 [J]. JN Engl J Med, 2015, 372(26): 2509-2520.

Please choose a citation manager

Content to export